Lyell Immunopharma, Inc.
NASDAQTotal Valuation
Lyell Immunopharma, Inc. carries a market capitalization of 352.13M, placing it among publicly traded companies globally. Its enterprise value stands at 177.12M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 352.13M |
| Enterprise Value | 177.12M |
Share Statistics
Lyell Immunopharma, Inc. currently has 24.50M shares outstanding.
| Shares Outstanding | 24.50M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 11,026.56, and the price-to-book ratio stands at 1.47.
| PE Ratio | N/A |
| PS Ratio | 11,026.56 |
| PB Ratio | 1.47 |
| P/TBV Ratio | 1.47 |
| P/FCF Ratio | -2.25 |
| P/OCF Ratio | -2.23 |
Enterprise Valuation
| EV / Sales | 6,559.93 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Lyell Immunopharma, Inc. maintains a current ratio of 5.36, meaning it holds 5.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 5.36 |
| Quick Ratio | 5.12 |
| Debt / Equity | 15.80 |
| Debt / EBITDA | -0.20 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -93.28 |
| Return on Assets (ROA) | -71.34 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Lyell Immunopharma, Inc.'s stock has gained approximately 18.2716% over the past 52 weeks. The 50-day moving average sits at 14.05, while the 200-day moving average is 20.30.
| Beta (5Y) | N/A |
| 52-Week Price Change | 18.2716% |
| 50-Day Moving Average | 14.05 |
| 200-Day Moving Average | 20.30 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Lyell Immunopharma, Inc. generated 27,000.00 in revenue and converted that into -248.48M in net income, yielding earnings per share of -11.73. EBITDA reached -180.65M, while operating income came in at -190.16M.
| Revenue | 27,000.00 |
| Gross Profit | N/A |
| Operating Income | -190.16M |
| Pretax Income | -248.48M |
| Net Income | -248.48M |
| EBITDA | -180.65M |
| EBIT | -190.16M |
| Earnings Per Share (EPS) | -11.73 |
Balance Sheet
Lyell Immunopharma, Inc. holds 204.10M in cash and equivalents against 36.93M in total debt, resulting in a net debt position of -72.98M. Total book value stands at 233.82M, with working capital of 173.67M providing operational flexibility.
| Cash & Cash Equivalents | 204.10M |
| Total Debt | 36.93M |
| Net Debt | -72.98M |
| Equity (Book Value) | 233.82M |
| Book Value Per Share | 9.54 |
| Working Capital | 173.67M |
Cash Flow
Lyell Immunopharma, Inc. produced -133.26M in operating cash flow over the past twelve months. After subtracting -711,000.00 in capital expenditures, free cash flow totaled -133.97M - equivalent to -6.32 per share.
| Operating Cash Flow | -133.26M |
| Capital Expenditures | -711,000.00 |
| Free Cash Flow | -133.97M |
| FCF Per Share | -6.32 |
Margins
Lyell Immunopharma, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -704,307.41 and net profit margin of -920,285.19 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -704,307.41 |
| Pretax Margin | -920,285.19 |
| Profit Margin | -920,285.19 |
| EBITDA Margin | -669,059.26 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -29.76 |
| FCF Yield | -44.52 |
Stock Splits
Lyell Immunopharma, Inc.'s most recent stock split took place on June 2, 2025 with a 20:1 split ratio.
| Last Split Date | 6/2/2025 |
| Split Ratio | 20:1 |
Scores
Lyell Immunopharma, Inc. posts an Altman Z-Score of -6.27, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -6.27 |